Vispacabtagene regedleucel

Vispacabtagene regedleucel (CB-010, vispa-cel) is an allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited) from Caribou Biosciences. An allogeneic anti-CD19 CAR-T cell therapy made with Cas9 chRDNA guides: the TRAC gene is knocked out to remove the T cell receptor, the anti-CD19 CAR is inserted into TRAC, and PD-1 is knocked out, a strategy designed to limit premature CAR-T cell exhaustion. Its furthest stage is phase 1, for relapsed or refractory B cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Company calls it its lead clinical-stage program; registry NCT04637763 (phase 1) is active, not recruiting. Whether it works in people has not been established unless a trial below reports it.